| Name | Title | Contact Details |
|---|
Global Care Quest is a Aliso Viejo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
What`s best for each patient drives our business. Through Center for Diagnostic Imaging`s national network, including Insight Imaging, we partner with healthcare providers to do what we do best — manage and deliver high-quality medical imaging (i.e. MRI, PET/CT, etc.) and related services (i.e. injections for pain) to enhance patient care. CDI offers the highest quality of care through a network of outpatient imaging centers and mobile facilities in more than thirty states. Headquartered in Minneapolis, Minnesota; the organization serves more than one million patients a year through a diverse set of customers including healthcare providers, managed care organizations, hospitals, health systems and payors (government and third party). Our local providers and partners are connected through CDI`s large network to other clinical providers and staff across the country. Through CDI`s sophisticated network, our partners access best practices and have the ability to consult with other specialized physicians, when needed, to improve patient care and outcomes. Being a national provider that is locally focused helps CDI provide each patient with the best of both worlds: individualized local patient care and extensive healthcare expertise.
Ehob Inc is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Jarvik Heart is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ValenTx was founded with the goal of treating some of the most pervasive health problems of our time: obesity and obesity-related metabolic disorders such as type-2 diabetes and hypertension. Our approach is to create a non-surgical, endoluminal bypass device that builds on the success of established medical interventions, resulting in a highly effective and least-invasive therapy. Current treatments for these diseases include surgery, pharmacology, and medically supervised lifestyle management. The risks, costs, and in some cases poor efficacy of these treatments have hampered their broad adoption by patients, physicians, and payers alike. A truly unmet clinical need exists for a therapy that can deliver the efficacy obtained through surgery, but without the risks and costs associated with surgical intervention. The ValenTx endoluminal bypass therapy mimics the attributes of a Roux-en-Y gastric bypass and is implanted through a non-surgical, endoscopic procedure. This procedure does not require gastric stapling or permanent changes to the patient`s anatomy. The device is removable, replaceable and designed so that the physician could change the therapeutic profile, thereby optimizing the treatment towards the individual patient`s needs. ValenTx has developed a strong intellectual property portfolio, which lies at the foundation of this therapy. The company has successfully conducted a series of clinical studies demonstrating the viability, safety, and efficacy of the therapy.